期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
Validation of Microbial Limit Test Methods of Tongmai Tangyanming Capsule
1
作者 Renhui YANG Yali YAO Xunrong ZHOU 《Agricultural Biotechnology》 CAS 2018年第1期104-108,共5页
[ Objectives] This study was conducted to establish a method for microbial limit test of Tongmai Tangyanming Capsule. [ Methods] According to the Chinese Pharmacopoei 2015 edition of the four general rules, the microb... [ Objectives] This study was conducted to establish a method for microbial limit test of Tongmai Tangyanming Capsule. [ Methods] According to the Chinese Pharmacopoei 2015 edition of the four general rules, the microbiological limits of non-sterile products were verified. [ Results] Tongmai Tangyanming Capsule has a strong inhibitory effect on Bacillus subtilis and Candida albicans. The antimicrobial activity was significantly eliminated after increasing the diluent ( 1 : 20) ; and the recoveries were in the range of 0.5 -2 when the total quantities of aerobic microbes were determined by dilution method (1:20). When the total quantities of mould and yeast were determined by dilution method (1:20), the recoveries were from 0.5 to 2, and Escherichia coli, cholate-tolerant Gram-negative bacteria and Salmonella can be detected by the test solution dilution method. [ Condusions] With the plate method, the total quantities of aerobic bacteria and the quantities of mould and yeast were examined by increasing diluent, and conventional method was used for examination of control bacteria including E. coli, cholatetolerant Gram-negative bacteria and Salmonella. This method has been proved effective for microbial limit test of Tongmai Tangyanming Capsule, and can effectively control the quality of the preparation. The method is accurate and reliable. 展开更多
关键词 Tongmai tangyanming Capsule Microbial limit test method Dilution method
下载PDF
Acute Toxicity Test of Chinese Herbal Compound Tongmai Tangyanming Capsule 被引量:1
2
作者 周训蓉 李平 屈相玲 《Agricultural Science & Technology》 CAS 2016年第10期2332-2333,2433,共3页
[Objective] This study was conducted to determine the safe dose of Tongmai Tangyanming capsule in clinic by evaluating its acute toxicity, so as to ensure clinical medication safety. [Method] The test was designed acc... [Objective] This study was conducted to determine the safe dose of Tongmai Tangyanming capsule in clinic by evaluating its acute toxicity, so as to ensure clinical medication safety. [Method] The test was designed according to "Technique Requirements of Research of New Chinese Medicine" and "Guide for Research of New Chinese Medicine", mice were intragastrically administrated with Tongmai Tangyanming capsule at a maximum concentration and a maximum volume, and the acute toxic response of mice was observed, so as to determine medi- na lethal dose (LDso) and maximum administration dosage of Tongmai Tangyanming capsule. [Result] The LD^o could not be detected in the test, and the maximum administration dosage of mouse was calculated to be 112.104 g of dried herbs/(kg.d), equivalent to 260 times of clinical dose of adult. [Conclusion] Chinese herbal compound Tongmai Tangyanming capsule has low acute toxicity, and its clinical dose is safe and reliable. 展开更多
关键词 Tongmai tangyanming capsule Acute toxicity test Median lethal dose Maximum administration dosage
下载PDF
通脉糖眼明胶囊对单纯型糖尿病视网膜病变患者VEGF水平的影响 被引量:15
3
作者 徐寒松 孔德明 向慧 《中国实验方剂学杂志》 CAS 北大核心 2011年第12期229-231,共3页
目的:观察通脉糖眼明胶囊对单纯型糖尿病视网膜病变(diabetic retinopathy,DR)患者血管内皮生长因子(vascular endothelial growth factor,VEGF)水平的影响,探讨通脉糖眼明胶囊治疗糖尿病视网膜病变的可能机制。方法:DR患者68例随机分... 目的:观察通脉糖眼明胶囊对单纯型糖尿病视网膜病变(diabetic retinopathy,DR)患者血管内皮生长因子(vascular endothelial growth factor,VEGF)水平的影响,探讨通脉糖眼明胶囊治疗糖尿病视网膜病变的可能机制。方法:DR患者68例随机分为通脉糖眼明胶囊治疗组36例,对照组32例,同时收集同年龄健康者30例为正常组,治疗组予通脉糖眼明胶囊治疗,比较治疗前后3组VEGF水平的变化。结果:DR患者VEGF水平显著升高,与正常组比较,差异有显著性意义(P<0.01);治疗8周后VEGF水平均下降,与治疗前相比差异有显著性意义(P<0.01);通脉糖眼明胶囊治疗组VEGF水平(116.50±22.34)下降尤为显著,与对照组(136.4±24.6)相比,差异有显著性意义(P<0.01)。结论:通脉糖眼明胶囊能有效降低DR患者VEGF水平,从而缓解DR病变进程。 展开更多
关键词 通脉糖眼明胶囊 糖尿病视网膜病变 血管内皮生长因子
原文传递
通脉糖眼明胶囊对单纯型糖尿病视网膜病变患者闪光视网膜电图及其振荡电位的影响 被引量:9
4
作者 徐寒松 孔德明 +2 位作者 李雪梅 赵胜 王明强 《中医杂志》 CSCD 北大核心 2007年第6期512-514,共3页
目的观察通脉糖眼明胶囊对单纯型糖尿病视网膜病变(DR)患者闪光视网膜电图(F-ERG)及其振荡电位(OPs)的影响。方法DR患者84只眼随机分为治疗组43只眼,对照组41只眼,同时收集同年龄健康者40只眼作为空白组。治疗组予通脉糖眼明胶囊治疗,... 目的观察通脉糖眼明胶囊对单纯型糖尿病视网膜病变(DR)患者闪光视网膜电图(F-ERG)及其振荡电位(OPs)的影响。方法DR患者84只眼随机分为治疗组43只眼,对照组41只眼,同时收集同年龄健康者40只眼作为空白组。治疗组予通脉糖眼明胶囊治疗,治疗前后3组分别进行F-ERG和OPs振幅、潜时的对比。结果DR患者F-ERG及OPs振幅降低,峰潜时延迟,与空白组比较差异有显著性意义(P<0.01);治疗后治疗组OPs波总振幅,F-ERGa、b,OPs前3子波振幅与峰潜时均得到明显恢复,与治疗前及对照组比较差异有显著性意义(P<0.01)。结论通脉糖眼明胶囊可明显改善DR患者的视网膜功能。 展开更多
关键词 糖尿病性视网膜病变 通脉糖眼明胶囊 闪光视网膜电图 振荡电位
下载PDF
通脉糖眼明胶囊的质量标准研究 被引量:1
5
作者 周训蓉 屈相玲 朴春梅 《中国药房》 CAS CSCD 2013年第11期1015-1017,共3页
目的:提高通脉糖眼明胶囊的质量标准。方法:采用薄层色谱(TLC)法对方中黄芪、丹参和三七进行定性鉴别,采用高效液相色谱法测定制剂中丹酚酸B的含量。结果:TLC斑点清晰,分离度好;丹酚酸B的进样量在0.076~3.890μg(r=0.9999,n=6)范围内... 目的:提高通脉糖眼明胶囊的质量标准。方法:采用薄层色谱(TLC)法对方中黄芪、丹参和三七进行定性鉴别,采用高效液相色谱法测定制剂中丹酚酸B的含量。结果:TLC斑点清晰,分离度好;丹酚酸B的进样量在0.076~3.890μg(r=0.9999,n=6)范围内与峰面积积分值呈良好线性关系,平均加样回收率为98.93%,RSD=3.57%(n=9)。结论:所建标准可用于通脉糖眼明胶囊的质量控制。 展开更多
关键词 通脉糖眼明胶囊 薄层色谱法 丹酚酸B 高效液相色谱法
原文传递
23G PPV联合通脉糖眼明胶囊对PDR患者疗效及血清胰岛素相关因子的影响 被引量:1
6
作者 冯劼 李培凤 《国际眼科杂志》 CAS 北大核心 2021年第9期1607-1611,共5页
目的:探究23G玻璃体切割术(PPV)后口服通脉糖眼明胶囊对增生性糖尿病视网膜病变(PDR)患者的临床疗效。方法:前瞻性随机对照研究。选取2018-02/2019-10我院收治的PDR患者98例109眼,随机分为对照组49例54眼仅行23G PPV术,观察组49例55眼23... 目的:探究23G玻璃体切割术(PPV)后口服通脉糖眼明胶囊对增生性糖尿病视网膜病变(PDR)患者的临床疗效。方法:前瞻性随机对照研究。选取2018-02/2019-10我院收治的PDR患者98例109眼,随机分为对照组49例54眼仅行23G PPV术,观察组49例55眼23G PPV术后口服通脉糖眼明胶囊治疗,每次750mg,3次/天,疗程12wk。记录两组患者术前、术后12wk最佳矫正视力(BCVA)、眼压、视野敏感度、黄斑中心凹厚度(CMT),测定血清胰岛素样生长因子-1(IGF-1)、血管内皮生长因子(VEGF)的变化,计算胰岛素抵抗指数(HOMA-IR);随访12wk观察手术并发症及复发率。结果:术后12wk,两组患者BCVA(LogMAR)、视野敏感度较术前改善(P<0.001),CMT下降(P<0.001),眼压无变化(P>0.05);观察组术后12wk BCVA、视野敏感度优于对照组(P<0.05),CMT低于对照组(P<0.05);术后12wk,两组患者血清IGF-1、VEGF、HOMA-IR均较术前降低(P<0.001),且观察组均低于对照组(P<0.001);两组并发症及复发率无差异(P>0.05)。结论:23G PPV术后口服通脉糖眼明胶囊较单独手术治疗更能促进术后视力恢复,提升视野敏感度,减轻胰岛素抵抗,降低IGF-1及VEGF水平,抑制视网膜新生血管生成及增殖,降低复发。 展开更多
关键词 增生性糖尿病性视网膜病变 23G玻璃体切割术 通脉糖眼明胶囊 视力 眼压 细胞因子
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部